The U.S. Food and Drug Administration authorized Philip Morris International to market 20 ZYN nicotine-pouch products as lower-risk alternatives to cigarettes [1].
This decision marks a significant shift in regulatory oversight for nicotine products. By allowing a manufacturer to explicitly claim a product is less harmful than combustible tobacco, the agency provides a legal pathway for companies to steer smokers toward non-combustible options.
The authorization was granted on Tuesday, June 30, 2026 [2]. The agency said its conclusion is based on the determination that these specific ZYN products pose a lower risk of several severe health conditions compared with traditional cigarettes [3].
According to the FDA, the authorized products carry a reduced risk of mouth cancer, heart disease, and lung cancer [3]. The agency also cited lower risks of stroke, emphysema, and chronic bronchitis [3].
Philip Morris International, the maker of ZYN, can now use these findings in its marketing materials for the 20 authorized products [1]. This regulatory move allows the company to position the pouches as a harm-reduction tool for adult smokers.
The FDA's decision follows a review of the risk profile associated with nicotine pouches. These products, which are placed under the lip, do not involve the combustion of tobacco, a primary cause of the respiratory and cardiovascular diseases associated with smoking.
“The FDA authorized Philip Morris International to market 20 ZYN nicotine-pouch products as lower-risk alternatives to cigarettes.”
This authorization represents a strategic pivot by the FDA toward a harm-reduction framework. By permitting the 'lower-risk' label, the agency is acknowledging that while nicotine remains addictive, the elimination of combustion significantly reduces the incidence of lethal cancers and cardiovascular events. This may accelerate the transition of adult smokers to nicotine pouches but could also create new challenges in preventing nicotine initiation among non-smoking youth.
